Patents by Inventor Gregory L. Verdine

Gregory L. Verdine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220082556
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Application
    Filed: December 21, 2020
    Publication date: March 17, 2022
    Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
  • Publication number: 20210405060
    Abstract: The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
    Type: Application
    Filed: January 28, 2021
    Publication date: December 30, 2021
    Inventors: Gregory L. VERDINE, M. James NICHOLS, Sharon A. TOWNSON, Uddhav Kumar SHIGDEL, Seung-Joo LEE, Dylan T. STILES, Neville J. ANTHONY
  • Patent number: 11198713
    Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: December 14, 2021
    Assignee: FOG PHARMACEUTICALS, INC.
    Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Ortet, Gregory L. Verdine
  • Publication number: 20210238646
    Abstract: The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or ?-lactam compounds) with such nucleic acids, vectors, and/or host cells.
    Type: Application
    Filed: January 29, 2021
    Publication date: August 5, 2021
    Inventors: Brian R. BOWMAN, Joshua A.V. BLODGETT, Gregory L. VERDINE, Daniel C. GRAY, Jay P. MORGENSTERN, Lucy FOULSTON, Keith ROBISON
  • Publication number: 20210179665
    Abstract: The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.
    Type: Application
    Filed: August 20, 2019
    Publication date: June 17, 2021
    Inventors: John Hanney McGee, Ty Matthew Thomson, Sebastian Christof Theodor Wahl, Gregory L. Verdine, Raheleh Rezaei Araghi, Yue-Mei Zhang, Mark Joseph Mulvihill
  • Publication number: 20210130821
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 6, 2021
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena ., Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 10989710
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 27, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Publication number: 20210115444
    Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
    Type: Application
    Filed: September 9, 2020
    Publication date: April 22, 2021
    Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Patent number: 10948495
    Abstract: The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: March 16, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Gregory L. Verdine, M. James Nichols, Sharon A. Townson, Uddhav Kumar Shigdel, Seung-Joo Lee, Dylan T. Stiles, Neville J. Anthony
  • Patent number: 10919936
    Abstract: The present invention provides stapled polypeptides of the Formulae (I) and (VI): and salts thereof; wherein the groups ; R1a, R1b, R1c, R2a, R3a, R2b, R3b, R4a, R4b, RA, RZ, L1a, L1b, L2, L3, XAA, v, w, p, m, s, n, t, and q are as defined herein. The present invention further provides methods of preparing the inventive stapled polypeptides from unstapled polypeptide precursors. The present invention further provides pharmaceutical compositions comprising a stapled polypeptide of Formula (I) or (VI), and methods of using the stapled peptides. The present invention also provides modifications of the staples post ring closing metathesis.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: February 16, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Gerard Hilinski
  • Patent number: 10907188
    Abstract: The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or ?-lactam compounds) with such nucleic acids, vectors, and/or host cells.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 2, 2021
    Assignee: Ginkgo Bioworks, Inc.
    Inventors: Brian R. Bowman, Joshua A. V. Blodgett, Gregory L. Verdine, Daniel C. Gray, Jay P. Morgenstern, Lucy Foulston, Keith Robison
  • Patent number: 10815482
    Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 27, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Meena, David Butler, Naoki Iwamoto, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Publication number: 20200247858
    Abstract: Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 6, 2020
    Applicant: FOG PHARMACEUTICALS, INC.
    Inventors: Gerard Hilinski, So Youn Shim, Matthew Reiser Patton, John Hanney McGee, Paula Ortet, Gregory L. Verdine
  • Publication number: 20200239533
    Abstract: The present invention provides peptides comprising a sequence of X-6X-5X-4X-3X-2X-1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.
    Type: Application
    Filed: November 26, 2019
    Publication date: July 30, 2020
    Inventors: Gregory L. VERDINE, John Hanney MCGEE
  • Patent number: 10724035
    Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: July 28, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Chandra Vargeese, Meena, Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
  • Publication number: 20200211673
    Abstract: Among other things, the present disclosure provides technologies for efficient and effective identification of ETaGs, for example, from fungi genomes. In some embodiments, provided technologies are particularly useful for identifying mammalian targets of biosynthetic products of fungi. In some embodiments, provided technologies are particularly useful for identifying and/or prioritizing human targets for drug development. In some embodiments, provided technologies are particularly useful for developing modulators for human targets based on biosynthetic products of fungi.
    Type: Application
    Filed: September 14, 2018
    Publication date: July 2, 2020
    Inventors: John Baxter Biggins, Brian Roger Bowman, Gregory L. Verdine
  • Patent number: 10590413
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 17, 2020
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Publication number: 20200080083
    Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
    Type: Application
    Filed: August 26, 2019
    Publication date: March 12, 2020
    Inventors: Chandra Vargeese, Meena ., Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
  • Publication number: 20200056173
    Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
    Type: Application
    Filed: May 3, 2017
    Publication date: February 20, 2020
    Inventors: Chandra Vargeese, Meena ., Nenad Svrzikapa, Susovan Mohapatra, Christopher J. Francis, Gregory L. Verdine, Anna Sokolovska
  • Patent number: 10533039
    Abstract: The present invention provides peptides comprising a sequence of X?6X?5X?4X?3X?2X?1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 14, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, John Hanney McGee